Literature DB >> 12225906

T cell response to 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) in multiple sclerosis patients.

P A Muraro1, M Kalbus, G Afshar, H F McFarland, R Martin.   

Abstract

T cell responses targeting myelin antigens are possibly involved in the pathogenesis of demyelinating diseases, such as multiple sclerosis (MS). Little is known about human T cell responses to 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), the third most abundant myelin protein. We examined the primary peripheral T cell response to CNPase and characterized CNPase-specific CD4+ long-term T cell lines (TCL) from MS patients and healthy donors. The strongest primary responses were found in two MS patients with very active disease and were directed against CNP(343-373). We identified immunodominant epitope clusters in the regions CNP(343-373) and (356-388) that were recognized in the context of MS-associated HLA-DR2 and DR4 molecules. These data provide the immunological basis for further investigation of CNPase as a potential target self-antigen in MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225906     DOI: 10.1016/s0165-5728(02)00229-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

Review 1.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

2.  Expression, purification, and initial characterization of different domains of recombinant mouse 2',3'-cyclic nucleotide 3'-phosphodiesterase, an enigmatic enzyme from the myelin sheath.

Authors:  Matti Myllykoski; Petri Kursula
Journal:  BMC Res Notes       Date:  2010-01-21

Review 3.  The myelin membrane-associated enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase: on a highway to structure and function.

Authors:  Arne Raasakka; Petri Kursula
Journal:  Neurosci Bull       Date:  2014-05-07       Impact factor: 5.203

4.  Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis.

Authors:  Jan D Lünemann; Harald Gelderblom; Mireia Sospedra; Jacqueline A Quandt; Clemencia Pinilla; Adriana Marques; Roland Martin
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

Review 5.  Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases.

Authors:  Sai Harsha Krovi; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2022-02-10       Impact factor: 10.983

6.  Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS.

Authors:  Doris Lambracht-Washington; Kevin C O'Connor; Elizabeth M Cameron; Andrea Jowdry; E Sally Ward; Elliot Frohman; Michael K Racke; Nancy L Monson
Journal:  J Neuroimmunol       Date:  2007-04-23       Impact factor: 3.478

7.  Identification of the low density lipoprotein (LDL) receptor-related protein-1 interactome in central nervous system myelin suggests a role in the clearance of necrotic cell debris.

Authors:  Anthony Fernandez-Castaneda; Sanja Arandjelovic; Travis L Stiles; Ryan K Schlobach; Kerri A Mowen; Steven L Gonias; Alban Gaultier
Journal:  J Biol Chem       Date:  2012-12-21       Impact factor: 5.157

8.  2'-3'-Cyclic Nucleotide 3'-Phosphodiesterase Inhibition by Organometallic Vanadium Complexes: A Potential New Paradigm for Studying CNS Degeneration.

Authors:  David C Platt; Jonathan Rink; Kamaljit Braich; Craig C McLauchlan; Marjorie A Jones
Journal:  Brain Sci       Date:  2021-04-30

9.  Myelin 2',3'-cyclic nucleotide 3'-phosphodiesterase: active-site ligand binding and molecular conformation.

Authors:  Matti Myllykoski; Arne Raasakka; Huijong Han; Petri Kursula
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

Review 10.  Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Christine Riedhammer; Robert Weissert
Journal:  Front Immunol       Date:  2015-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.